Shares of HCL Tech, Angel One and Delta Corp will be in focus as the companies will announce their third quarter results later today.

Biocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated. This followed a...

Biocon share price: This upgrade reflects a more positive outlook on the company following recent favorable news flow, particularly concern...

CLSA has upgraded ONGC to "High Conviction Overweight-PF," citing multiple production and realization triggers, alongside attractive valuat...

Biocon Share Price: Biocon shares surged 5.4% after FDA classified its Bengaluru facility as Voluntary Action Indicated (VAI). The stock is...

Dr Reddy's Laboratories (DRL) and Intas Pharmaceuticals, both Indian companies, are reportedly in the race to acquire the biosimilar produc...

The investment will help Biocon Biologics' acquisition of the biosimilars business of its partner Viatris.

Biocon Biologics Ltd has made several key leadership appointments, including appointing Rhonda Duffy as Chief Operating Officer and Sandeep...

Ashok Leyland's Q4 net sales are expected to increase by 35% YoY to Rs 11,786 crore, with net profit likely to decline 10% to Rs 807 crore....

Siddharth Mittal, CEO & Managing Director, Biocon, said, “The strong year-on-year growth of the segment was driven by both our API and Form...

LIC stock has fallen 13 per cent from its issue price of Rs 949 to Rs 826. In that process, shareholders of the company have lost over Rs 7...

Biocon reported a 64 per cent jump in its net profit for the quarter ending March 2019.

Fulphila is expected to contribute to Biocon’s revenue in FY19, as well as to its profits through a profitshare arrangement with Mylan.

This product is a part of the biosimilars portfolio being developed jointly by Biocon and Mylan, the company said in a BSE filing.

The company said it does not expect the CRL to impact the timing of the launch of biosimilar Pegfilgrastim in the US market.

The company, however, said it does not expect this CRL to impact the commercial launch timing of biosimilar Pegfilgrastim in the US.

"Biocon aims to provide high quality biosimilars to patients across the world, both in emerging and developed markets," Kiran Mazumdar-Shaw...